Pharma BD Deal Intelligence
A scale play still in motion: Ligand's ~$739M cash-plus-CVR bid for XOMA Royalty adds seven commercial products and pushes its portfolio past 200 assets, with a holding-company restructuring already needed before the deal even closes in Q3 2026.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →The acquisition will add more than 120 assets across commercial, clinical, and preclinical stages to Ligand's existing portfolio, bringing its total to more…
Ligand's Todd Davis stated the deal presents a compelling opportunity for us to strengthen and diversify our portfolio across all stages of clinical…
Amendment No. 1 to the Agreement and Plan of Merger, dated May 16, 2026, adding XOMA Royalty Holdings Corporation (a Nevada subsidiary) as a party to effect a…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Ligand (LGND) entered a definitive agreement to acquire XOMA Royalty (XOMA) for $39.00/share cash, ~$739M equity value, plus a non-tradeable CVR entitled to 75% of net proceeds from certain pending XOMA litigation. Expands Ligand's royalty portfolio past 200 assets and adds 7 commercial products; expected immediately accretive to Ligand adjusted EPS. On May 16, 2026 the parties signed Amendment No. 1 (8-Ks filed May 18, 2026) adding a newly formed Nevada subsidiary, XOMA Royalty Holdings Corporation, so the merger is effected via a holding-company reorganization (Flex Merger Sub merges into HoldCo) rather than directly into XOMA; the $39.00/share cash consideration and CVR terms are unchanged. The deal remains pending and is expected to close in Q3 2026, subject to XOMA stockholder approval and HSR clearance.
XOMA's royalty portfolio spans the indications of its underlying licensed products. The flagship asset is Roche's Vabysmo (faricimab), a bispecific anti-VEGF/anti-Ang-2 antibody approved for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO) — addressing roughly 1.6 million US nAMD patients per AAO. Day One's Ojemda (tovorafenib) is a type II RAF inhibitor approved April 2024 for relapsed/refractory pediatric low-grade glioma with BRAF fusions or rearrangements (~1,000-1,500 US incident pLGG cases annually per CBTRUS). Zevra's Miplyffa (arimoclomol) is approved for Niemann-Pick disease type C, an ultra-rare lysosomal storage disorder with ~300-400 US patients. Additional late-stage programs include Takeda's mezagitamab (autoimmune cytopenias), osavampator (treatment-resistant depression), volixibat (cholestatic pruritus), and OHB-607 (bronchopulmonary dysplasia). Unmet need varies by indication but is concentrated in pediatric oncology and ultra-rare disease.
Royalty aggregator competition is led by Royalty Pharma (RPRX, ~$3B+ annual royalty receipts), HealthCare Royalty Partners (private), Healthcare Royalty (HCRX), and DRI Healthcare Trust. Ligand and XOMA were the two listed mid-cap aggregators; their combination eliminates a direct competitor and creates the third-largest publicly traded royalty platform behind Royalty Pharma and HCRX. The CVR structure (75% of net proceeds from XOMA's pending Janssen Biotech litigation) preserves upside for legacy XOMA holders. Underlying assets compete in their own categories: Vabysmo competes with Regeneron's Eylea/Eylea HD and Roche's Lucentis biosimilars in retina; Ojemda competes with Novartis's Mekinist+Tafinlar combo and Day One's own positioning in BRAF-altered pLGG (XOMA receives a low-single-digit royalty); Miplyffa competes with Mallinckrodt's VTS-270 (intrathecal cyclodextrin, in development) and is currently the only FDA-approved NPC treatment. Five to ten years post-close, Ligand's path depends on whether Vabysmo and Ojemda hit consensus growth (double-digit) and whether Ligand can sustain its acquisition cadence to keep replacing aging royalties before the underlying assets reach LOE.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Ligand Pharmaceuticals Incorporated / XOMA Royalty Corporation (this deal) | 2026 | $739M | — |
| Ligand Pharmaceuticals Incorporated / APEIRON Biologics AG | 2024 | $100M | — |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Becton, Dickinson and Company / C.R. Bard Inc. | 2017 | $24.0B | 77 |
| Johnson & Johnson / Synthes Inc. | 2011 | $19.7B | 77 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |